Navigation Links
Anti-Toxoplasma Performance Panel from SeraCare Provides Broad Sample of New, Challenging Material
Date:7/16/2013

Milford, Massachusetts (PRWEB) July 16, 2013

SeraCare Life Sciences, a provider of high quality biological materials that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, announced it has introduced a new AccuSet™ anti-Toxoplasma performance panel. This is the newest addition to the SeraCare line of performance panels designed to help IVD manufacturers effectively challenge new assays during development.

"The demand for Toxoplasma testing in the healthcare industry remains consistently high, requiring the development of new and rigorous testing platforms," said Kim Anderson, Product Manager, IVD Research Business Unit at SeraCare. Screening for the Toxoplasma gondii parasite is performed widely in pregnant women, infants born to infected women, and people with severely weakened or compromised immune systems, creating strong demand for rigorous anti-Toxoplasma assays.

SeraCare’s new AccuSet™ Anti-Toxoplasma gondii Mixed Titer Performance Panel (PTT202) helps IVD manufacturers respond to this market need. It comprises 21 members with a broad range of reactivity for IgG and IgM antibodies and contains donor material representing newer infections, which is critical for IVD manufacturers to effectively challenge new assays.

"Identifying donors who are newly infected with the Toxoplasma gondii parasite but already beginning to demonstrate antibody reactivity is inherently demanding," said Anderson. "SeraCare’s unrivaled sourcing network enabled us to find these donors and develop a panel that can provide our customers with the high degree of confidence they need when challenging the anti-Toxoplasma assays they are currently developing."

SeraCare’s new AccuSet™ Anti-Toxoplasma gondii Mixed Titer Performance Panel is available immediately worldwide. For more information, contact SeraCare Customer Service at 1-800-676-1881 or visit http://www.seracare.com.

About SeraCare Life Sciences, Inc.

SeraCare, a portfolio company of Linden Capital Partners, works with diagnostics researchers, IVD manufacturers and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality controls, research panels, SeraCon™ processed plasma, specialty human blood products and Complete BioCollections™ materials. SeraCare helps bridge the gap between today’s diagnostic solutions and tomorrow’s emerging technologies for molecular diagnostics, next generation sequencing, and companion diagnostics. For more information, visit http://www.seracare.com.

About Linden Capital Partners

Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden currently has investments in middle market platforms in the products, distribution, and services segments of healthcare. For additional information about Linden, please refer to the firm's website at http://www.lindenllc.com.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10919460.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Arizona State University engineers aim to improve performance of technology in extreme environments
2. City of Mason and Top Gun Sales Performance Announce $4 Million Investment In New Corporate Headquarters
3. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
4. McLean Report on nanotechnology that may enhance medication delivery and improve MRI performance
5. New Daily Disposable Multifocal Contact Lenses from CooperVision Offer Comfort, Performance, Health, and Convenience to Fit Your Life
6. Maxx Performance Joins GreenPalm to Promote Sustainable Harvest of Palm Oil
7. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
8. A KAIST research team has developed a high performance flexible solid state battery
9. Elsevier Launches New Journal: Performance Enhancement & Health
10. Nanoresonators might improve cell phone performance
11. New design could improve condenser performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... According to a new ... Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, ... Development, Disease-Risk) - Global Forecast to 2021" published ... USD 53.34 Billion by 2021 from USD 27.95 ... 13.8% during the forecast period (2016-2021). ...
(Date:2/17/2017)... Feb. 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... its oral peptide drug candidates, PTG-100 and PTG-200, ... European Crohn,s and Colitis Organization (ECCO).  The ECCO ... Spain from February 15 – 18, ... data on Protagonist drug candidates PTG-100 and PTG-200. ...
(Date:2/16/2017)... Calif. and GREENWICH, Conn. ... a private investment firm focused on venture growth ... the promotion of Josh Richardson , M.D. ... on investments in biotechnology companies.  He is a ... played important roles in Longitude,s investments in Aimmune ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor Therapeutics, ... clinical-stage biotechnology company developing first-in-class biological therapies for ... it has elected to terminate its license agreement ... receptor agonists, including Cenderitide. "Our decision ... as we prioritize our efforts to advance our ...
Breaking Biology Technology:
(Date:1/23/2017)... DENVER , Jan. 23, 2017  The latest ... biometric smartphone prices have dropped dramatically. The quarterly average ... Q1 2013 to $276 in Q4 2016.  There are ... average price of $116, up from just 28 a ... According to Maxine Most , Acuity ...
(Date:1/19/2017)... Oregon and PUNE, India , January 19, 2017 ... Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," ... growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... owing to high-level security for both public and private sectors. ... ...
(Date:1/18/2017)... Jan. 18, 2017  In vitro diagnostic (IVD) companies ... and acquisitions (M&A), and Kalorama Information expects that trend ... have been shifting. Generally, uncertainty in reimbursement and healthcare ... U.S. has changed the acquisitions landscape. Instead of looking ... companies buying partners outside of their home country and ...
Breaking Biology News(10 mins):